Drug news
LCZ 696 has priority review at FDA and decision in August 2015.- Novartis
Novartis announced that the FDA has granted priority review designation to LCZ 696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation accelerates the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition. For LCZ 696 this reduces the total review time from 12 to 8 months, meaning the FDA could make a decision on approval in August 2015.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.